390 results about "Tumor targeting" patented technology

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses a polypeptide-based PROTAC condensation body as well as a preparation method and application of the polypeptide-based PROTAC condensation body. The polypeptide-based PROTAC aggregate comprises an HER2 (human epidermal growth factor receptor) targeting module, an EGFR (epidermal growth factor receptor) targeting module, a VHL E3 ligase targeting module and a self-assembly module. The polypeptide-based PROTAC condensation body can dynamically enrich E3 ligase VHL and promote efficient ubiquitination degradation of HER2, EGFR and downstream signal channel protein of HER2 and EGFR, the degradation efficiency of HER2 and EGFR protein can reach 92%, the degradation efficiency of downstream signal channel protein such as SOS2 and RAS can reach 80%, and in addition, the polypeptide-based PROTAC condensation body has the advantages that the polypeptide-based PROTAC condensation body can be used as an efficient ubiquitination condensation body; the polypeptide-based PROTAC condensation body has the characteristics of tumor targeting and long-acting retention, and dose-dependent tumor specific accumulation and retention can be realized through in-situ self-assembly.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention discloses iron oxide nanoparticles capable of responding to particle size change in a tumor microenvironment and a preparation method of the iron oxide nanoparticles, and belongs to the technical field of biomedical nano materials. The nano-particle comprises an iron oxide nano-crystal core with the particle size of 3-5nm and a tumor microenvironment response layer coating the surface of the iron oxide nano-crystal core. The response layer contains groups, such as disulfide bonds, enzyme digestion peptide fragments and the like, which can respond to acidic pH, high-concentration reduced glutathione or matrix metalloproteinase and other tumor characteristic stimuli to generate structural changes. In a tumor microenvironment, the hydration particle size of the nanoparticles can be directionally and controllably converted from 3-20 nm to 20-100 nm (or reversely). The preparation method mainly comprises two steps of preparing the core by a thermal decomposition method and modifying the surface response layer. The technical problems of insufficient tumor targeted enrichment capacity, limited imaging contrast and difficulty in balancing permeation and retention caused by fixed particle size of the existing iron oxide nanoparticles are solved, and the accuracy and efficiency of tumor diagnosis and treatment can be remarkably improved.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to tumor-targeted trimeric polypeptides based on the homotrimerization region from collagen XV or XVIII and which contain domains capable of specifically binding to and activating receptors of the TNFR family of costimulatory receptors as well as to the uses thereof in the treatment of cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano bionic bimetallic MOF and a preparation method and application thereof. The nano bionic bimetallic MOF has a core-shell structure and comprises an inner core and a cell membrane coating the surface of the inner core, the inner core is nano bimetal MOF, and the nano bimetal MOF contains a glucose transport inhibitor and a photosensitizer. Mn / Fe-MOF is synthesized by using a solvothermal method, a glucose transport inhibitor (BAY-876) and a photosensitizer (CyI) are loaded in the Mn / Fe-MOF, and the Mn / Fe-MOF is subjected to cell membrane bionic modification to obtain a core-shell structure which is used for enhancing tumor targeting. The hypoxia microenvironment responds to release oxygen and is actively targeted to a breast cancer tumor site, and the effect of overcoming tumor drug resistance synergistically by multiple mechanisms is verified by depending on a cell / animal model.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The present invention relates to a bispecific antibody that specifically binds to VISTA and MSLN, and uses thereof. The bispecific antibody exhibits significant immuno-oncological activity and ADCC activity compared to a monospecific antibody, degrades target proteins through internalization activity, and possesses tumor-targeting ability, and thus can be advantageously used for the prevention or treatment of various cancers.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.

The invention discloses a tumor targeting boron-containing Fe3O4-based nano-enzyme and a preparation method and application thereof, and belongs to the technical field of tumor treatment.The tumor targeting boron-containing Fe3O4-based nano-enzyme takes boron-10 doped Fe3O4 nano-enzyme as a boron-containing drug group and an enzyme activity center, and the surface of the tumor targeting boron-containing Fe3O4-based nano-enzyme is modified with a targeting group; the targeting group is chitosan-folic acid-polyethylene glycol. The tumor targeting boron-containing Fe3O4-based nano-enzyme has relatively strong selective enrichment capacity on tumor cells such as melanoma, shows good biocompatibility and low toxicity, and has relatively strong apoptosis induction and killing effects on the melanoma cells in boron neutron capture therapy; meanwhile, active oxygen free radicals can be generated in boron neutron capture therapy to generate an oxidative damage effect.

The present invention relates to multispecific antigen binding proteins that comprise an antigen-binding regions specific for a tumor-associated antigen (TAA), an antigen-binding region that specifically binds an epitope of a γδ T cell receptor (TCR), a γδ T cell-activating cytokine, and optionally, a γδ T cell co-stimulatory agonist. The γδ T cell-activating cytokine preferably is at least 5 one of an interleukin 21 receptor (IL21R) agonist and an interleukin 15 receptor (IL15R) agonist. The γδ T cell co-stimulatory agonist cytokine preferably is at least one of a 4-1BB agonist, a CD27 agonist and a GITR agonist. The multispecific antigen binding proteins of the invention specifically redirect and activate γδ T cell to lyse targeted tumor cells. The invention further relates to the use of such multispecific antigen binding proteins in the treatment of cancer, preferably a cancer 10 expressing the TAA.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The application discloses a rare earth nanoparticle-organic photosensitizer composite material and application thereof. By introducing rare earth doped nanoparticles as an energy conversion medium, direct activation of excited triplet states of an organic photosensitizer and sensitized production of singlet oxygen under excitation of radionuclides (e.g., 64Cu, 67Cu, 90Y, 111In, 177Lu, etc.) are realized. 18 F、 99m Tc、 177 Lu, etc.) excitation, the rare earth doped nanoparticles respond to CL and the rare earth ions reach an excited state after various high-energy radiation. Subsequently, through an interface energy transfer process, the excited state energy of the rare earth ions is directly transferred to the excited triplet state of the organic photosensitizer, and then singlet oxygen is generated, realizing tumor cell killing. The nanocomposite material is surface modified to load iRGD peptides to realize in vivo tumor targeting. 18 F-FDG (fluorodeoxyglucose) can realize tumor targeting through abnormal glucose uptake of tumors. The combination of the two realizes double targeting of in vivo tumors, and enhances the anti-tumor efficacy and safety.

The invention provides a targeted degradable protein and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the targeted degradation protein is SEQ ID NO.1. When the targeted degradation protein is used for treating breast cancer, target protein degradation can be directly mediated, so that the effect of the target protein is weakened fundamentally, the targeted degradation protein only needs to be combined with the target protein with very strong affinity, specific epitopes do not need to be combined, the design difficulty is low, and the number of adaptive targets is large. Therefore, the targeted degradation protein provided by the invention takes the membrane molecule with high expression of tumor specificity as the effect protein, so that the dual effects of tumor targeting and mediated endocytosis are realized.

The invention provides a bacterial outer membrane vesicle drug carrier with a targeting effect and preparation, and relates to the technical field of biological medicines.The bacterial outer membrane vesicle protein ClyA derived from an escherichia coli W3110 strain is combined with iRGD protein capable of being combined with an integrin receptor alpha v beta 3, a ClyA-iRGD-pGEX-6P-1 recombinant plasmid for expressing ClyA-iRGD fusion protein is constructed, and the ClyA-iRGD-pGEX-6P-1 recombinant plasmid is used for preparing the bacterial outer membrane vesicle drug carrier with the targeting effect. By endogenous expression of the plasmid in W3110 escherichia coli, the C-iRGD-OMVs which has a tumor targeting effect and shows ClyA-iRGD fusion protein on the surface is prepared. The C-iRGD-OMVs shows efficient targeting binding capacity to MCF-7 breast cancer cells, overcomes the defect that iRGD single peptide is prone to aggregation and crystallization, has the potential of loading drugs, lays a foundation for the C-iRGD-OMVs serving as a targeting carrier for delivering breast cancer treatment drugs, and is expected to be further developed into a targeting treatment preparation for breast cancer.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.

The invention belongs to the technical field of biological medicines, and discloses an engineered bacterium for in-situ expression of a microtubule inhibition protein in a tumor and application of the engineered bacterium. The engineering bacteria are formed by constructing microtubule inhibition protein genes to an expression vector and finally transferring the expression vector into bacteria. The engineering bacterium can be colonized in a tumor microenvironment in a targeted manner, expresses microtubule inhibition protein, effectively inhibits tumor cells and remarkably inhibits solid tumor growth, and is excellent in safety.

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

The invention discloses an adoptive cell therapy system with tumor targeted activation and acid neutralization characteristics. The system is prepared by adhering a micron-sized layered double-metal hydroxide patch to the surface of an immune cell. The immune cells are any one of macrophages, dendritic cells, T cells and NK cells. The layered double-metal hydroxide patch is adhered to the surface of the immune cell in a manner of co-incubation with the immune cell. Before co-incubation, the layered double-metal hydroxide patch is modified by PEG-COOH in advance and is combined with a specific targeting ligand to form a surface functional layer for realizing efficient selective adhesion of the patch to immune cells and reducing non-specific binding. According to the adoptive cell therapy system, the cell homing effect is utilized, the immune cells carrying the layered double-metal hydroxide patches are enriched at the tumor site, the STING pathway of the immune cells is activated, the anti-tumor effect of the immune cells is promoted, meanwhile, locally free H < + > is consumed, and potent immunotherapy for solid tumors is achieved.

The invention discloses a preparation method of silver-loaded nano-cluster-adriamycin composite hydrogel. The method comprises the following steps: preparing a silver nano-cluster from an AgNO3 solution and a gallic acid solution; preparing a prepolymer from chitosan, hyaluronic acid, an acetic acid solution and methacrylic anhydride; mixing silver nanoclusters, a doxorubicin hydrochloride solution and the prepolymer, and adding a photoinitiator to obtain preliminarily formed hydrogel; and immersing the primarily formed hydrogel into a sodium citrate solution to obtain the silver-loaded nano-cluster-adriamycin composite hydrogel. The composite hydrogel prepared by the invention has a pH-responsive drug release characteristic, the drug release is accelerated in an acidic environment, and the drug release is slow in a neutral environment; the antibacterial agent has an inhibiting effect on bacteria such as escherichia coli and staphylococcus aureus, and shows good antibacterial performance; the toxicity to cancer cells is obviously higher than that of normal cells, and certain tumor targeting is achieved; and the polymer has good mechanical strength and good swelling performance in different pH environments, and has a wide application prospect.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment.In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.

The invention relates to the field of biological medicine, in particular to application of NPEPL1-targeted small molecule compounds in preparation of tumor targeted therapy drugs, and four small molecule compounds, namely C301-9181, E859-1332, L281-0443 and C679-2629, which have a hepatocellular carcinoma cell killing effect and high NPEPL1 affinity are obtained for the first time. The small molecule compound realizes tumor targeted therapy by targeting NPEPL1 protein in tumor cells, and can be used for developing tumor targeted therapy drugs. According to the present invention, the potential treatment effect of the targeted intervention NPEPL1 on hepatocellular carcinoma and other malignant solid tumors with high NPEPL1 expression is provided, the optimal small molecule compound C301-9181 is obtained through layer-by-layer screening, the small molecule compound can be used for preparing the NPEPL1-targeting anti-tumor targeting drugs, the drug research and development blank in the NPEPL1 targeting treatment field is filled, and the broad application prospect is provided.

Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and / or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat neoplastic diseases including solid tumors and lymphomas.

The invention discloses an engineered exosome preparation with tumor targeting and specific gripper response release functions as well as a preparation method and application of the engineered exosome preparation. The preparation comprises a myocardial cell exosome, an NK cell biotinylation activation antibody, a tumor disease biotinylation antibody, streptavidin, a tumor fiber matrix FAP targeting peptide and a tumor matrix enzyme response peptide, and anchoring is carried out through an acetamide compound-polyethylene glycol anchor point platform. The engineering bispecific exosome preparation with good tumor targeting and barrier breakthrough ability and immune cell activation effect is prepared, and the preparation breaks a solid tumor compact fiber barrier and increases NK cell infiltration by utilizing the fibrosis treatment ability of the myocardial cell exosome and the capture and targeting effects of an anchor point platform; the natural killer cells are in close contact with tumor cells, the lasting tumor cell killing effect is achieved, and the tumor matrix environment is fundamentally changed.